MX349354B - Derivado de cicloalcano. - Google Patents
Derivado de cicloalcano.Info
- Publication number
- MX349354B MX349354B MX2014009637A MX2014009637A MX349354B MX 349354 B MX349354 B MX 349354B MX 2014009637 A MX2014009637 A MX 2014009637A MX 2014009637 A MX2014009637 A MX 2014009637A MX 349354 B MX349354 B MX 349354B
- Authority
- MX
- Mexico
- Prior art keywords
- group
- alkyl group
- alkoxy
- alkyl
- halogenated
- Prior art date
Links
- 150000001924 cycloalkanes Chemical class 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 12
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 5
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 4
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 3
- 125000005843 halogen group Chemical group 0.000 abstract 3
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 108010052164 Sodium Channels Proteins 0.000 abstract 1
- 102000018674 Sodium Channels Human genes 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Anesthesiology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012025754 | 2012-02-09 | ||
| JP2012259122 | 2012-11-27 | ||
| PCT/JP2013/052985 WO2013118854A1 (ja) | 2012-02-09 | 2013-02-08 | シクロアルカン誘導体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014009637A MX2014009637A (es) | 2015-06-23 |
| MX349354B true MX349354B (es) | 2017-07-24 |
Family
ID=48947609
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014009637A MX349354B (es) | 2012-02-09 | 2013-02-08 | Derivado de cicloalcano. |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US8889741B2 (enExample) |
| EP (2) | EP2813491B1 (enExample) |
| JP (2) | JP5997710B2 (enExample) |
| KR (1) | KR20140127238A (enExample) |
| CN (1) | CN104185629B (enExample) |
| AU (1) | AU2013218592B2 (enExample) |
| BR (1) | BR112014019478A2 (enExample) |
| CA (1) | CA2864222C (enExample) |
| CO (1) | CO7151511A2 (enExample) |
| CY (1) | CY1118572T1 (enExample) |
| DK (1) | DK2813491T3 (enExample) |
| ES (2) | ES2659434T3 (enExample) |
| HR (1) | HRP20161713T1 (enExample) |
| HU (2) | HUE037048T2 (enExample) |
| IL (1) | IL234014A (enExample) |
| IN (1) | IN2014MN01577A (enExample) |
| LT (1) | LT2813491T (enExample) |
| MX (1) | MX349354B (enExample) |
| NZ (1) | NZ628096A (enExample) |
| PH (2) | PH12014501804B1 (enExample) |
| PL (1) | PL2813491T3 (enExample) |
| PT (1) | PT2813491T (enExample) |
| RS (1) | RS55671B1 (enExample) |
| RU (1) | RU2635354C2 (enExample) |
| SG (1) | SG11201404707VA (enExample) |
| SI (1) | SI2813491T1 (enExample) |
| SM (2) | SMT201700053T1 (enExample) |
| TW (1) | TWI612042B (enExample) |
| WO (1) | WO2013118854A1 (enExample) |
| ZA (1) | ZA201405801B (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2586213T3 (es) | 2011-10-31 | 2016-10-13 | Xenon Pharmaceuticals Inc. | Compuestos de bencenosulfonamida y su uso como agentes terapéuticos |
| JP6014155B2 (ja) | 2011-10-31 | 2016-10-25 | ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． | ビアリールエーテルスルホンアミドおよび治療剤としてのそれらの使用 |
| US8889741B2 (en) * | 2012-02-09 | 2014-11-18 | Daiichi Sankyo Company, Limited | Cycloalkane derivatives |
| BR112014029161A2 (pt) | 2012-05-22 | 2017-06-27 | Genentech Inc | benzamidas n-substituídas e seu uso no tratamento de dor |
| BR112015000187A2 (pt) | 2012-07-06 | 2017-06-27 | Genentech Inc | benzamidas substituídas com n e métodos de uso das mesmas |
| BR112015022488A2 (pt) | 2013-03-14 | 2017-07-18 | Genentech Inc | triazolopiridinas substituídas e métodos de uso das mesmas |
| EP2974730B1 (en) * | 2013-03-14 | 2018-01-31 | Daiichi Sankyo Company, Limited | Drug for respiratory diseases |
| BR112015023397A2 (pt) | 2013-03-15 | 2017-07-18 | Genentech Inc | benzoxazois substituídos e métodos de uso dos mesmos |
| CR20160296A (es) | 2013-11-27 | 2016-09-20 | Genentech Inc | Benzamidas sustituidas y métodos para usarlas |
| EP3166939B1 (en) | 2014-07-07 | 2019-06-05 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
| WO2016191312A1 (en) | 2015-05-22 | 2016-12-01 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
| MA42683A (fr) | 2015-08-27 | 2018-07-04 | Genentech Inc | Composés thérapeutiques et leurs méthodes utilisation |
| PE20181003A1 (es) | 2015-09-28 | 2018-06-26 | Genentech Inc | Compuestos terapeuticos y sus metodos de uso |
| JPWO2017078123A1 (ja) * | 2015-11-06 | 2018-09-13 | 第一三共株式会社 | ジメトキシベンジル基の脱離方法 |
| CN108495851A (zh) | 2015-11-25 | 2018-09-04 | 基因泰克公司 | 取代的苯甲酰胺及其使用方法 |
| EP3854782A1 (en) | 2016-03-30 | 2021-07-28 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
| KR102366077B1 (ko) * | 2016-05-20 | 2022-02-21 | 제논 파마슈티칼스 인크. | 벤젠술폰아미드 화합물 및 치료제로서의 그의 용도 |
| SG11201903348UA (en) * | 2016-10-17 | 2019-05-30 | Genentech Inc | Therapeutic compounds and methods of use thereof |
| MA46615A (fr) * | 2016-10-27 | 2019-09-04 | Bristol Myers Squibb Co | Inhibiteurs de nav1.7 de type acyl-sulfonamide |
| KR20190086772A (ko) * | 2016-12-09 | 2019-07-23 | 제논 파마슈티칼스 인크. | 벤젠술폰아미드 화합물 및 치료제로서의 그의 용도 |
| WO2018175707A1 (en) | 2017-03-24 | 2018-09-27 | Genentech, Inc. | 4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors |
| AU2018338098B2 (en) | 2017-09-20 | 2024-02-22 | Abm Therapeutics Corporation | Cyclic iminopyrimidine derivatives as kinase inhibitors |
| EP3759098A1 (en) * | 2018-02-26 | 2021-01-06 | Genentech, Inc. | Pyridine-sulfonamide compounds and their use against pain and related conditions |
| EP3774801A1 (en) | 2018-03-30 | 2021-02-17 | F. Hoffmann-La Roche AG | Fused ring hydro-pyrido compounds as sodium channel inhibitors |
| TW202003490A (zh) | 2018-05-22 | 2020-01-16 | 瑞士商赫孚孟拉羅股份公司 | 治療性化合物及其使用方法 |
| BR112020024729A2 (pt) | 2018-06-13 | 2021-03-23 | Xenon Pharmaceuticals, Inc. | compostos de benzenossulfonamida e seu uso como agentes terapêuticos |
| CA3104913A1 (en) | 2018-08-31 | 2020-03-05 | Xenon Pharmaceuticals Inc. | Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors |
| IL279810B2 (en) | 2018-08-31 | 2025-03-01 | Xenon Pharmaceuticals Inc | Heteroaryl-modified sulfonamide compounds and their use as medicinal agents |
| KR20210107698A (ko) * | 2018-12-26 | 2021-09-01 | 라퀄리아 파마 인코포레이티드 | Nav1.7 및 Nav1.8 차단제로 쓰이는 헤테로환 유도체 |
| US12625275B2 (en) * | 2023-01-18 | 2026-05-12 | Qualcomm Incorporated | Virtual positioning signal measurements |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6222048B1 (en) | 1995-12-18 | 2001-04-24 | Merck Frosst Canada & Co. | Diaryl-2-(5H)-furanones as Cox-2 inhibitors |
| WO2006038594A1 (ja) | 2004-10-04 | 2006-04-13 | Ono Pharmaceutical Co., Ltd. | Ｎ型カルシウムチャネル阻害薬 |
| KR20080021030A (ko) * | 2005-05-16 | 2008-03-06 | 버텍스 파마슈티칼스 인코포레이티드 | 이온 채널 조절인자로서의 바이사이클릭 유도체 |
| EP2173743A2 (en) | 2007-07-13 | 2010-04-14 | Icagen, Inc. | Sodium channel inhibitors |
| WO2010035166A1 (en) | 2008-09-23 | 2010-04-01 | Pfizer Limited | Benzamide derivatives |
| HUE025013T2 (hu) * | 2009-01-12 | 2016-04-28 | Pfizer Ltd | Szulfonamid-származékok |
| JP5872552B2 (ja) * | 2010-07-09 | 2016-03-01 | ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ | 化学化合物 |
| CA2804593C (en) * | 2010-07-09 | 2015-11-24 | Pfizer Limited | Biphenyloxybenzensulphonamide derivatives useful as sodium channel inhibitors |
| JP5860045B2 (ja) | 2010-07-09 | 2016-02-16 | ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ | 化合物 |
| ES2586213T3 (es) * | 2011-10-31 | 2016-10-13 | Xenon Pharmaceuticals Inc. | Compuestos de bencenosulfonamida y su uso como agentes terapéuticos |
| US8889741B2 (en) * | 2012-02-09 | 2014-11-18 | Daiichi Sankyo Company, Limited | Cycloalkane derivatives |
-
2013
- 2013-01-31 US US13/756,173 patent/US8889741B2/en active Active
- 2013-02-07 TW TW102104725A patent/TWI612042B/zh not_active IP Right Cessation
- 2013-02-08 CN CN201380017715.1A patent/CN104185629B/zh not_active Expired - Fee Related
- 2013-02-08 HR HRP20161713TT patent/HRP20161713T1/hr unknown
- 2013-02-08 AU AU2013218592A patent/AU2013218592B2/en not_active Ceased
- 2013-02-08 HU HUE16193142A patent/HUE037048T2/hu unknown
- 2013-02-08 MX MX2014009637A patent/MX349354B/es active IP Right Grant
- 2013-02-08 WO PCT/JP2013/052985 patent/WO2013118854A1/ja not_active Ceased
- 2013-02-08 BR BR112014019478A patent/BR112014019478A2/pt not_active Application Discontinuation
- 2013-02-08 JP JP2013557586A patent/JP5997710B2/ja not_active Expired - Fee Related
- 2013-02-08 IN IN1577MUN2014 patent/IN2014MN01577A/en unknown
- 2013-02-08 EP EP13746373.3A patent/EP2813491B1/en active Active
- 2013-02-08 KR KR1020147021798A patent/KR20140127238A/ko not_active Abandoned
- 2013-02-08 SG SG11201404707VA patent/SG11201404707VA/en unknown
- 2013-02-08 HU HUE13746373A patent/HUE031450T2/en unknown
- 2013-02-08 NZ NZ628096A patent/NZ628096A/en not_active IP Right Cessation
- 2013-02-08 LT LTEP13746373.3T patent/LT2813491T/lt unknown
- 2013-02-08 ES ES16193142.3T patent/ES2659434T3/es active Active
- 2013-02-08 RU RU2014136463A patent/RU2635354C2/ru not_active IP Right Cessation
- 2013-02-08 SI SI201330423A patent/SI2813491T1/sl unknown
- 2013-02-08 PT PT137463733T patent/PT2813491T/pt unknown
- 2013-02-08 ES ES13746373.3T patent/ES2613078T3/es active Active
- 2013-02-08 DK DK13746373.3T patent/DK2813491T3/en active
- 2013-02-08 RS RS20170101A patent/RS55671B1/sr unknown
- 2013-02-08 PL PL13746373T patent/PL2813491T3/pl unknown
- 2013-02-08 CA CA2864222A patent/CA2864222C/en not_active Expired - Fee Related
- 2013-02-08 SM SM20170053T patent/SMT201700053T1/it unknown
- 2013-02-08 EP EP16193142.3A patent/EP3144300B1/en not_active Not-in-force
-
2014
- 2014-08-06 ZA ZA2014/05801A patent/ZA201405801B/en unknown
- 2014-08-07 IL IL234014A patent/IL234014A/en not_active IP Right Cessation
- 2014-08-11 PH PH12014501804A patent/PH12014501804B1/en unknown
- 2014-09-05 CO CO14195847A patent/CO7151511A2/es unknown
- 2014-09-30 US US14/502,708 patent/US9493448B2/en not_active Expired - Fee Related
-
2015
- 2015-11-27 PH PH12015502675A patent/PH12015502675A1/en unknown
-
2016
- 2016-08-26 JP JP2016165515A patent/JP6154052B2/ja not_active Expired - Fee Related
- 2016-09-19 US US15/269,485 patent/US9845313B2/en not_active Expired - Fee Related
-
2017
- 2017-01-24 SM SM201700053T patent/SMT201700053B/it unknown
- 2017-01-31 CY CY20171100142T patent/CY1118572T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12014501804A1 (en) | Cycloalkane derivative | |
| IN2014DN03063A (enExample) | ||
| PH12016501028A1 (en) | Prodrugs of pyridone amides useful as modulators of sodium channels | |
| NZ703064A (en) | Inhibitors of hepatitis c virus | |
| JO3453B1 (ar) | مشتقات البنزاميد لتثبيط نشاط abl1 و abl2 و bcr-abl1 | |
| PH12016500553A1 (en) | Substituted quinolizine derivatives useful as hiv integrase inhibitors | |
| MD20160078A2 (ro) | Inhibitori ai Syk | |
| MX2014013957A (es) | Derivados de 3,4-dihidro-2h-pirido[1,2-a]pirazin-1,6-diona sustituidos utiles para el tratamiento de la enfermedad de alzheimer (inter alia). | |
| MX2015011984A (es) | Inhibidores de bromodominio de dihidro-pirrolopiridinona. | |
| MY177250A (en) | Novel nicotinamide derivative or salt thereof | |
| MD20150075A2 (ro) | Compuşi tetraciclici heterociclu-substituiţi şi metode de utilizare a acestora pentru tratamentul bolilor virale | |
| JO3261B1 (ar) | مشتق بيريدين أحادي الحلقة | |
| PH12014500308A1 (en) | Cyclopropaneamine compound | |
| MX2014006366A (es) | Metodos y composiciones para reducir la grasa y los adipocitos del cuerpo. | |
| MX2016007440A (es) | Inhibidores del bromodominio. | |
| MX341341B (es) | Derivados de benzamida y su uso como inhibidores de proteina de choque termico 90 kda (hsp90). | |
| GEP20207070B (en) | New isoindoline or isoquinoline compounds, a process for their preparation and pharmaceutical compositions containing them | |
| PH12015502429A1 (en) | Dicarboxylic acid compound | |
| MY195177A (en) | Pyrazole Derivative or Pharmaceutically Acceptable Salt Thereof | |
| MX2019010756A (es) | Derivados novedosos de imidazo[4,5-c]quinolina como inhibidores de cinasa 2 rica en repetición de leucina (lrrk2). | |
| MX379704B (es) | Compuestos de 6,7-dihidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxamida | |
| MX2022006003A (es) | Glucolipidos y composiciones farmaceuticas de los mismos para usarse en terapia. | |
| RU2015155032A (ru) | Тилозиновые производные и способ их получения | |
| MX2015015485A (es) | Derivado de glicinamida alfa-sustituida. | |
| PH12016501645A1 (en) | Aminopyrazolone derivative |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |